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Abstract Background The majority of hospitalised
patients have drug-related problems. Clinical pharmacist
services including medication history, medication recon-
ciliation and medication review may reduce the number of
drug-related problems. Acute and emergency hospital ser-
vices have changed considerably during the past decade in
Denmark, and the new fast-paced workflows pose new
challenges for the provision of clinical pharmacist service.
Objective To describe and evaluate a method for a clinical
pharmacist service that is relevant and fit the workflow of
the medical care in the acute ward. Setting Acute wards at
three Danish hospitals. Methods The clinical pharmacist
intervention comprised medication history, medication
reconciliation, medication review, medical record entries
and entry of prescription templates into the electronic
medication module. Drug-related problems were catego-
rised using The PCNE Classification V6.2. Inter-rater
agreement analysis was used to validate the tool. Accep-
tance rates were measured as the physicians’ approval of
prescription templates and according to outcome in the
PCNE classification. Main outcome measure Acceptance
rate of the clinical pharmacists’ interventions through the
described method and inter-rater agreement using the
PCNE classification for drug-related problems. Results
During 17 months, 188 patients were included in this study
(average age 72 years and 55 % women). The clinical
pharmacists found drug-related problems in 85 % of the
patients. In the 1,724 prescriptions, 538 drug-related
problems were identified. The overall acceptance rate by
the physicians for the proposed interventions was 76 %
(95 % CI 74–78 %). There was a substantial inter-rater
agreement when using the PCNE classification system.
Conclusion The methods for a clinical pharmacist service
in the acute ward in this study have been demonstrated to
be relevant and timely. The method received a high
acceptance rate, regardless of no need for oral communi-
cation, and a substantial inter-rater agreement when clas-
sifying the drug-related problems.
Keywords Acceptance rate  Acute ward  Clinical
pharmacy  Denmark  DRP classification  Drug-
related problems  Electronic prescription template 
Medication history  Medication reconciliation 
Medication review
Impacts on practice
• Clinical pharmacist services in the acute ward need to
fit the high-paced workflow to benefit the health care
professional teams and thereby the patients.
• The method for a clinical pharmacist service in the
acute ward described here fits an intensive workflow,
identifies multiple drug-related problems and yields a
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high acceptance rate of the interventions, regardless of
no oral communication.
• Classifying drug-related problems in the acute wards
can be done well with ‘The PCNE Classification’
system to categorise problems, interventions and
outcomes.
Introduction
The majority of hospitalised patients have drug-related
problems (DRPs) [1–11] which are events or circumstances
involving drug therapy that actually or potentially can
interfere with the desired health outcomes [12]. The total
cost of drug-related morbidity and mortality exceeds the
cost of the medications themselves [3]. Nevertheless, drug-
related morbidity and mortality are often preventable, and
pharmaceutical care services may reduce the number of
DRPs, adverse drug events (ADEs), the length of hospital
stays, and the cost of care [4, 13].
It has been described how clinical pharmacists (CPs)
participate in various stages of the medication process such
as compiling the medication history [14], medication rec-
onciliation [15] and performing medication reviews [12,
16] and clinical pharmacy may benefit all stages of the
medication process [4, 6, 17–23].
Acute and emergency hospital services have changed
over the past decade in Denmark. One of the recent
developments is the merging of all acute and emergency
services and reception of patients into one ward [24]. The
workflow, however, at these new acute wards, differ from
the workflow at specialised wards. All patients are received
in the acute ward, regardless of their medical problem.
Within 6 h, the patients should be attended to by nurses,
secretaries, laboratory technicians, and physicians and
allocated to a dedicated specialised ward. Clinical phar-
macist services must be relevant and timely to meet this
workflow. Projects involving the implementation of clini-
cal pharmacy services in various Danish hospitals have
evolved around three main areas; medication history,
medication reconciliation and medication review [23–26].
The learning and results from these projects can form the
basis for what a clinical pharmacist service could comprise
in the acute ward.
Most hospitals in Denmark use a form of electronic
medical record and medication module, such as a computer
physician order entry (CPOE). Electronic prescribing has
proven to reduce drug prescription errors [27], and CPOE
with clinical decision support (CDS) can improve patient
safety [8, 28]. Still, occurrence of DRPs persists and
pharmacists can enhance patient safety, despite CPOE [7,
8]. Electronic prescribing presents possibilities for
standardisation of prescriptions using CDS such as pre-
scription templates. This provides a tool for communicat-
ing pharmacists’ interventions.
How interventions are communicated between pharma-
cists and physicians highly affect acceptance rates, and
face-to-face communication has been recognised to be an
important factor leading to the highest acceptance rate [29–
31]. However, this form of communication can be difficult
in acute wards with a high-paced workflow. The rate with
which pharmacists’ interventions are accepted and imple-
mented by physicians in hospital settings varies consider-
ably in the literature, though most acceptance rates
reported are between 50 and 100 % [1, 21–23, 29, 31–39].
Again, this is highly dependent on the way the acceptance
rate is defined within the study [29].
Throughout the literature, DRPs are classified into
various systems, some validated, others invented to fit the
purpose of the specific study [40]. On the European level,
The Pharmaceutical Care Network Europe (PCNE) has
developed ‘The PCNE Classification for Drug Related
Problems’, which has proven to be a useful tool in doc-
umenting clinical pharmacist services in the hospital set-
ting [9]. The PCNE system is continuously being
developed [40] and might be a good option for a useful
system for research and practise in the acute wards as
well.
Aim of the study
The aim of this intervention study was to describe and
evaluate a method for a clinical pharmacist service that is
relevant and fits the workflow of the medical care in the
acute ward.
Methods
Inclusion
Patients were included from the acute wards in three
non-university hospitals in one of the five Danish
regions. Patients were included 2–5 days a week between
08:00 and 17:00. Medical patients aged 18 years or
older, taking four or more drugs a day (including over-
the-counter (OTC) drugs and supplements) were eligible
for inclusion. Patients in terminal or palliative care,
patients too ill to wait for a physician before the CP
interview, patients transferred directly from other hospi-
tals in the region and patients unable to understand the
consent form written in Danish, were not eligible for
inclusion.
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Intervention
Three CPs, all employed by the hospital pharmacy carried
out the interventions. The pharmacist’s intervention com-
prised a medication history, medication reconciliation,
medication review, a written CP entry in the medical
record, and entry of allergy information and prescriptions
templates into the electronic medication module (EMM).
Procedure for the pharmacist’s intervention is described in
details in ‘‘Appendix 1’’.
The purpose of the patient interviews was to obtain a
secondary medication history [18] and to identify DRPs
such as side-effects, lack of effect, or non-compliance. The
interview revolved around the patient’s own drugs (POD) if
these were present [41–43] or previous medication lists.
During the interviews, patients were asked specifically
about their use of OTCs, herbal- or dietary supplements,
and use of medications that were not taken orally (e.g.
inhalers, eye-, nasal- or dermatological preparations) [18,
44].
Medication reconciliation was done by compiling all
available information on the medication history and com-
paring this to the prescriptions in the EMM [45].
The medication review comprised an assessment of
indications, contraindications, dosages, effects, interac-
tions, availability, and costs of each prescription. National
as well as local treatment guidelines were used in the
assessment, along with summary of product characteristics
(SPC) for the specific drug. The CPs documented the
proposed changes in therapy in the medical record.
Finally, all prescriptions, including recommended
changes, were entered into the EMM. Until approved
electronically by a physician, the clinical pharmacist pre-
scriptions were complete but inactive template
prescriptions.
This approach was chosen to ensure that all details of
the proposed interventions would be implemented in the
prescriptions. If the physician agreed, an electronic
approval was all that was needed to effectuate the proposed
intervention. Otherwise, the template could be dismissed.
The CP interview was conducted before the physician
saw the patients. After each interview, the CP performed
the rest of the intervention while the physician examined
the patient. The intention was that all CP electronic entries
should be completed within 1 h.
The CP intervention was solely based on communica-
tion through medical record entries and prescription tem-
plates in EMM to fit the high-pace of workflow in the acute
wards, where face-to-face communication is difficult and
time-consuming. Additionally, prescription templates
minimised the time required by the physician to approve
and implement the interventions.
Data collection
The time spent on patient interviews and on the rest of the
intervention, was recorded. All pharmacist interventions
and their outcomes were recorded and categorised. Each
outcome was collected from the patient’s medical record
and EMM a few days after the intervention. All pharma-
cists’ allergy and prescription templates in EMM were
recorded as well as the following physician-approved
prescriptions.
Assessment of acceptance rates
The physicians’ acceptance rates of the CP interventions
were assessed as the proportion of prescription templates
approved by the physicians, and as the proportion of
intervention outcomes classified as ‘problem totally’ or
‘partially solved’ or ‘no need to solve’, according to the
PCNE classification.
Classification of drug-related problems
The PCNE classification V6.2 [12] was used to classify
identified problems, causes and interventions by each CP
finding the DRP. The same system was used to classify the
outcome of the interventions by one evaluating pharmacist.
The PCNE classification V6.2 was translated into Dan-
ish and adapted slightly for the purpose of the CP report
form. The adaptation consisted of an extra level of detail
(subdomain) to the intervention-codes (I-codes) I3.1, I3.2,
I3.3 and I3.4. The translated and adapted version is avail-
able in ‘‘Appendix 2’’. The DRPs are reported in the ori-
ginal level of detail.
To validate the usability of The PCNE Classification V6.2
as a tool for the CP intervention in acute wards, an inter-rater
reliability study was made using Cohen’s Kappa statistics
[46]. The two pharmacists who had performed the majority
of all interventions, each rated a random sample (generated
by Research Randomizer [47]) of approximately one-fifth of
the other pharmacist’s medication reviews. The DRPs were
rated using a copy of the CP’s entry in the medication record
and EMM, but blinded to the first pharmacist’s ratings. Only
the PCNE-codes ‘P’, ‘C’ and ‘I’ were compaired since the
‘O’-codes were rated retrospectively by one rater only. Both
the original I- PCNE classification and the adapted I -PCNE
classification with an extra subdomain were analysed with
Kappa statistics.
Statistics
Data were collected in standardised report forms by the CP
and entered into Microsoft Access. IBM SPSS Statistics for
Int J Clin Pharm
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Windows, Version 20.0.0 (IBM Corp. Released 2011, Ar-
monk, NY: IBM Corp) and Microsoft Excel were used for
Kappa- and descriptive statistics.
Results
Demographics
From March 2010 to July 2011, three CPs screened 1,775
patients for eligibility in the acute wards in Naestved,
Nykoebing F and Slagelse hospitals in Denmark. More
than half of the patients did not meet the inclusion criteria,
mostly by not taking four or more drugs, while some
declined to participate or were already evaluated by a
physician.
The 188 patients included were 26–97 years old and
used 4–22 drugs per day, including OTCs and supplements
(Table 1). Of the 168 patients who stated their height and
weight, the average Body Mass Index was 26.6. After the
acute ward, the patients were mainly transferred to a gen-
eral internal medicine ward (39 %), a cardiac medicine
ward (28 %) or respiratory medicine ward (14 %).
Intervention
In 181 (96 %) of the cases, the CPs obtained medication
history by including patient interviews. One to five sources
of information were used to compile the medication history.
In 62 and 22 % of cases respectively, two or three sources of
information were used. Most frequently, the source was
previous medical records or POD, besides the patient inter-
view. The physicians documented their primary medication
history in 78 % of the included patients’ medical records.
The median duration of a patient interview was 11 min,
including time to obtain informed consent. Subsequently, the
CP reconciled and reviewed the medications, entered the
prescription templates and the notes in the medical records.
Only 10 (5 %) cases lasted more than 60 min (65–95 min).
As the CPs became familiar with the method (especially
entering the prescription templates into the EMM), the time
needed for the intervention decreased from average 39 min
for the first half of patients to average 29 min for the second
half. Table 2 shows the data from the interventions distrib-
uted at each centre.
The overall physician acceptance rate was 76 % (95 %
CI 74–78 %) of the proposed prescriptions templates. The
lowest acceptance rates were seen in patients who were
discharged within 24 h (n = 36). The intervention also
included the CPs entering allergy status into the EMM as a
template. The overall acceptance rate of this was 46 %
(95 % CI 37–55 %).
Drug-related problems
In total, 1724 prescriptions were assessed by the CPs, and
DRPs were identified in one-third of the prescriptions as
shown in Table 3.
The most frequent problem identified was ‘Drug treat-
ment more costly than necessary’. Another frequent prob-
lem was ‘Effect of drug treatment not optimal’, these two
problems accounted for 51 % of all DRPs. Nearly half of
Table 1 Characteristics of the
patients upon admission to the
acute ward by centre
Characteristics of patients by centre Naestved Nykoebing Slagelse All
Patients, n 104 27 57 188
Age, mean (SD) 71.4 (±11.3) 72.4 (±12.9) 73.3 (±14.0) 72.1 (±12.4)
Gender female, % 59 52 51 55
Medications per pt., median (range) 7 (17) 11 (13) 8 (15) 8 (17)
Admission orders per pt.,
median (range)
9 (23) 9 (26) 12 (20) 10 (26)
Medical history (five main
diagnose areas), %
Heart diagnosis 62 63 42 56
Lung diagnosis 21 33 39 29
Muscoskeletal diagnosis 24 19 25 23
Endocrine diagnosis 18 26 18 19
Gastrointestinal diagnosis 7 15 23 13
Cause of admission, %
Cardiovascular 38 22 9 27
Respiratory 22 37 30 27
Miscellaneous symptoms 18 22 12 17
Nervous system 4 4 14 7
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causes for the DRPs were found to be ‘More cost-effective
drug available’, ‘Inappropriate drug’ or ‘Dose too low/
high’. The drug specific interventions most proposed were
‘Drug changed to equivalent drug’ or ‘Drug stopped’,
accounting for half of the interventions.
In two-thirds of cases, the outcomes were ‘‘Problem
totally solved’’. When including ‘Problem partially solved’
and ‘No need or possibility to solve problem’ the accep-
tance rate was 73 % (95 % CI 69–77) of all interventions
on drug-level.
Details of the distribution of all DRPs in the study using
the PCNE classification are given in ‘‘Appendix 3’’.
The drugs most recurrently involved in DRPs were
drugs for the cardiovascular system, alimentary tract and
metabolism, and nervous system. Table 4 shows the dis-
tribution of the CPs’ interventions by the anatomical
therapeutic chemical (ATC) classification system [48].
From the centres Naestved and Slagelse, 36 randomly
selected patients taking 353 drugs, were rated by two raters
independently. Overall, there was a substantial inter-rater
agreement, with Kappa[0.6 [46], as presented in Table 5.
The codes causing most disagreement were the P-codes;
P3.1, P1.2 and P3.2, the C-codes; C1.7 and C3.1 and the
I-codes; I3.1, I3.2 and I3.5. The most frequent disagree-
ment factor was whether or not there actually was a
problem, cause or intervention which was denominated P0,
C0 and I0, respectively. These accounted for nearly half of
the disagreements.
Discussion
Acceptance rates
The method described and evaluated in this study using
electronic prescription templates to communicate the pro-
posed interventions overall had a high acceptance rate. The
acceptance of 76 % is similar to other studies where
pharmacists reconciled and/or reviewed medications in
hospital settings, with acceptance rates between 69 and
89 % [1, 22, 31, 49]. However, these studies all used oral
communication when proposing interventions. Other Dan-
ish studies have used written communication in the form of
paper notes or entries into the medical record. These
studies in general have a lower acceptance rate of 39–70 %
[23, 26, 39, 50]. In this perspective, the proposed method of
prescription templates appears to be a good alternative to
oral communication when the workflow or the time avail-
able limits the possibility of oral communication. Corre-
spondingly, electronic prescribing in the hospital setting
has been associated with an increased implementation of
clinical pharmacologists’ drug recommendations when
compared with handwritten prescribing on paper [27].
The acceptance rate on the prescription template method
includes templates suggesting generic substitution. This type
of templates were not categorised as DRPs when evaluating
the interventions on drug-level, thus this acceptance rate is
slightly lower, at 73 %. Still, it is a high acceptance rate
which indicates that the interventions have been timely and
relevant for the physicians in the acute ward setting.
Timing
In many cases, a large part of the patients prescriptions
cannot be optimised until the diagnosis is present. Thus, the
Table 2 Clinical pharmacist
interventions by centre
Interventions by centre Naestved Nykoebing Slagelse All
Clinical pharmacists (n) 1 1 1 3
Physicians involved (n) 93 6 21 116
Pharmacist prescription templates (n) 731 234 512 1,477
Approved pharmacist prescriptions (n) 557 153 411 1,121
Accept rate prescription entries, % (95 % CI) 76 (73–79) 65 (59–71) 80 (77–83) 76 (74–78)
Pharmacist time spent (min)
Patient interview, median (range) 10 (36) 13 (41) 14 (19) 11 (42)
Pharmacist intervention, median (range) 25 (71) 36 (77) 40 (59) 30 (86)
Total time per patient, median (range) 35 (106) 65 (79) 51 (81) 44 (106)
Table 3 Clinical pharmacist interventions on drug-level
Interventions by drug-level
Drugs, n 1,724
Patients with drug-related problem, n (%) 153 (85)
Drug-related problems found, n 538
Drug-related problems found, % (95 % CI) 31 (29–33)
Interventions, n (%) 537 (31)
Acceptance rate for Interventions
Problem totally/partially solved/not
needed to solve, % (95 % CI)
73 (69–77)
Problem not solved, % (95 % CI) 19 (16–22)
Outcome unknown, % (95 % CI) 8 (6–10)
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medication review will be less time-consuming when the
prescriptions is only checked for unusual dosages, costs,
interactions, and contraindications. This makes it possible
to perform the intervention in less than 1 h as the method
suggests, and to deliver the interventions to the physician
in a timely manner. In a time-study conducted at Naestved
Hospital in the same period as the present study, the phy-
sicians’ workflow in the acute ward was timed [51]. The
study showed that physicians spend an average of 45 min
on a patient in the acute ward. With a mean time of 30 min
for the CP’s intervention, the prescription templates will be
complete when the physician is ready to make the admis-
sion orders. In the present study, the CPs spent a median of
11 min on the patient interviews (including informed
consent). Other studies have found similar results from 10
to 20 min for pharmacists’ medication history-taking [18,
52]. The medication history is thus relatively time-con-
suming, albeit it is the foundation for both a correct med-
ication reconciliation and review that has proved to be
clinically important [14, 18, 19, 44, 53].
Interventions
The most frequent types of interventions were ‘changed
drug’, ‘drug stopped’, ‘prescriber informed’, ‘changed
dose’ and ‘drug started’. This reflects the typical focus
areas of rational pharmacotherapy in the elderly and in
polypharmacy patients [9, 54, 55] and is similar to other
studies classifying DRPs with the PCNE classification [9,
56, 57].
The typical approach has to be changed in more than
just the timing when performing medication review in the
acute ward setting. At the time the CP performs the med-
ication review, the new diagnosis has not been made,
laboratory tests and blood work have not yet been done and
only few vital parameters are measured. Thus, the medi-
cation review is based on optimisation of the pharmaco-
therapy that has no relation to the current symptoms only.
This method classifies as ‘The Intermediate medication
review’ in PCNE definitions [12]. What also deviates from
medication reviews on non-acute patients is the focus on
medication-related symptoms in the acute ward. The CP
would record in the pharmacist’s entry if any of the med-
ications could be related to the admission cause symptoms.
Classification of DRPs
Overall, The PCNE Classification V6 was suitable for
classifying the DRPs in the study. It was a great advantage
to allocate the DRPs into problems, interventions and
outcomes separately, which other classification systems
lack [58]. The PCNE classification category ‘Cause’ was of
less use in this study. The cause of the DRP was not always
readily found in the acute ward setting, and it was usually
not essential in order to solve the problem. Correspond-
ingly, ‘Cause’ is the category scoring lowest kappa-value.
Within the I-categories, the greatest disagreement was one
rater choosing ‘drug changed’ or ‘drug stopped’ and the
other rater choosing ‘prescriber informed only’ or ‘no
intervention’, respectively. This disagreement originates
from the method, rather than the classification system. If
the CP proposed to stop a drug, the CP would simply omit
making a prescription template of that drug and document
this in the medical record. This could be rated either as
‘drug stopped’, ‘prescriber informed only’ or ‘no inter-
vention’ since no template was made. In brief, The PCNE
Table 4 Distribution of clinical pharmacist interventions by Ana-
tomical Therapeutic Index (ATC)
Distribution of interventions by drug ATC-group 1. Level (%)
A Alimentary tract and metabolism 23
B Blood and blood forming organs 9
C Cardiovascular system 26
D Dermatologicals 0
G Genito-urinary system and sex hormones 1
H Systemic hormonal preparations, excluding sex
hormones and insulins
3
J Antiinfectives for systemic use 1
L Antineoplastic and immunomodulating agents 1
M Musculo-skeletal system 5
N Nervous system 17
P Antiparasitic products, insecticides and repellents 1
R Respiratory system 10
S Sensory organs 1
V Various 0
X No ATC-code (supplements) 2
Table 5 Inter-rater agreement of the PCNE classification for DRPs
analysed using Kappa statistics
Kappa inter-rater agreement Kappa CI 95 % P
P-codes 0.614 (0.543–0.685) \0.001
C-codes 0.601 (0.532–0.670) \0.001
I-codes adapted 0.674 (0.605–0.743) \0.001
I-codes original 0.700 (0.631–0.769) \0.001
Kappa Interpretationa
\0 Poor agreement
0.00–0.20 Slight agreement
0.21–0.40 Fair agreement
0.41–0.60 Moderate agreement
0.61–0.80 Substantial agreement
0.81–1.00 Almost perfect agreement
a Landis and Koch [46]
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Classification V6 performs as a usable system for the
clinical pharmacist’s intervention in the acute ward, how-
ever the ‘Cause’-section may have too many and some
irrelevant options for use in the acute ward, giving this a
lower inter-rater agreement score.
Strengths and limitations
This study included a wide range of medical patients from
three different acute wards, though the most critically ill
patients were not included. The method has disadvantages
regarding the limited clinical information available on the
patient when performing medication review at the acute
ward. Even with limited clinical information, DRPs were
identified in 85 % of the patients, and the acceptance rate
of proposed interventions was high. However, it has not
been investigated whether this method caused a higher
workload on the physicians or other health care personnel
in the acute ward. Nor has the physicians’ opinion of the
CP’s service been studied.
Clinical relevance
A large proportion of DRPs identified and a high acceptance
rate of the interventions, does not guarantee a reduction of
ADEs or a better clinical outcome for the patient. Only few
randomised controlled studies have investigated the clinical
effect of in-hospital clinical pharmacist services [21–23, 37,
56, 59]. Whether the clinical pharmacist service in the acute
ward in this study will improve the clinical outcome for the
patients is yet to be investigated.
Conclusion
The methods for a clinical pharmacist service in the acute
ward described in this study are demonstrated to be rele-
vant, timely and useful to the physicians. The CPs identi-
fied at least one DRP in 85 % of patients and intervened in
every third prescription. The method presents with a good
acceptance rate, regardless of no need for oral communi-
cation, and a substantial inter-rater agreement when clas-
sifying the DRPs.
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Appendix 1: Procedure for the clinical pharmacist
service in the acute ward
Workflow acute ward Clinical
pharmacist
task
Procedure
Patient is admitted to the
acute ward
Screen Inclusion criteria:
Age C18
Drugs C4 (incl. OTCs
and supplements)
Able to give consent in
Danish
Not in palliative or
terminal care
Patient is evaluated by
triage nurse
Assess patient Proceed if patient can
wait more than
15 min. for a physician
Patient is allocated a bed,
changes clothes and is
interviewed by nurse
Compile
preliminary
medication
list
Check relevant sources
for information on
medications, if
present:
Previous medical
records
Referral papers
Home care or nursing
home notes, or
personal medication
lists
Patient has EKG taken
and blood drawn
Patient
interview
Medication history: (see
details below)
Explain purpose of the
interview
Obtain POD if present
Comprise medication
history using the POD
and/or preliminary
medication list as
interview guide
Ask if the patient has
drug-related questions
for the clinical
pharmacist.
Patient waits for
physician (time
dependent on triage)
Patient is interviewed by
physician
Medication
review
Medication
reconciliation:
Compare obtained
medication list to the
prescriptions in EMM
Obtain further
information from
pharmacy dispensing
records or GP
if needed
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Medication history
• Compile medication history using the PODs and/or
preliminary medication list as interview guide
• Ask specifically for OTCs such as; pain-, allergy- or
alimentary preparations.
• Ask specifically for herbal- and dietary supplements
• Ask specifically for non-oral medications, such as;
inhalation-, ophthalmic-, dermatologic-, nasal-, sublin-
gual-, or rectal preparations
• Ask for the patient’s perceived effect of the medication
• Ask about compliance and adverse drug reactions
• Ask about known allergies or alerts, such as; antibiot-
ics, opiates, NSAIDs, iodide, food dyes
• Also ask relatives or caregivers if they are present,
especially if patient has aphasia, dyspnoea or otherwise
cannot participate well in the interview
Medication review
• Check that medication prescribed is indicated and not
contra-indicated (SPC)
• Check for untreated indications or missing prophylaxis
medications (treatment guidelines)
• Check that the medication is effective for patient
(interview)
• Check that dosing and dosing intervals are within
recommendations (SPC)
• Check for cost-effectiveness (formulary and guidelines)
• Check for clinical relevant drug–drug interactions with
good documentation (SPC or online interaction tool)
• Check for side effects, compliance or concordance
problems (interview)
• Check that relevant monitoring is planned (e.g. blood
work, blood pressure, blood glucose)
• Check for prescription errors especially in high alert
medications such as; antibiotics, antidepressants, anti-
psychotics, antithrombotics and coagulation inhibitors,
benzodiazepines, cytostatics, diuretics, insulin, NSA-
IDs, strong opioids (EMM)
(Reference tools in brackets)
Appendix 2
See Table 6.
Appendix 1 continued
Workflow acute ward Clinical
pharmacist
task
Procedure
Patient is examined by
physician
Medication review: (see
details below)
Verify if dosage,
duration, indications,
contraindications are
within
recommendations (SPC
or treatment guidelines)
Check for interactions
(SPC or online
interaction tool)
Check for more cost-
effective drug (hospitals
formulary)
Documentation Enter clinical
pharmacist’s note in
medical record with
headings:
Secondary medication
history
Summary of patient
interview (compliance,
ADR, DRP found)
Proposed drug
interventions
Interactions and/or
allergies
Physician dictates
entry to medical
record
Prescription
templates
Enter allergy status
templates and
prescription templates
for the patients
medication including
proposed
interventions
into the EMM
Physician writes
admission orders and
approves or dismisses
prescription
templates
Patient is transferred
to specialised
ward
OTC over-the-counter drugs, POD patient’s own drugs, EMM elec-
tronic medication module, GP general practitioner, SPC summary of
product characteristics, ADR adverse drug reaction, DRP drug related
problem
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See Table 7.
Table 7 Distribution of the drug-related problems on PCNE Classification codes
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